143 related articles for article (PubMed ID: 19053886)
1. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.
Mark T; Martin P; Leonard JP; Niesvizky R
Expert Opin Investig Drugs; 2009 Jan; 18(1):99-104. PubMed ID: 19053886
[TBL] [Abstract][Full Text] [Related]
2. Milatuzumab - a promising new immunotherapeutic agent.
Berkova Z; Tao RH; Samaniego F
Expert Opin Investig Drugs; 2010 Jan; 19(1):141-9. PubMed ID: 19968579
[TBL] [Abstract][Full Text] [Related]
3. CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
Stein R; Mattes MJ; Cardillo TM; Hansen HJ; Chang CH; Burton J; Govindan S; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5556s-5563s. PubMed ID: 17875789
[TBL] [Abstract][Full Text] [Related]
4. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
Govindan SV; Cardillo TM; Sharkey RM; Tat F; Gold DV; Goldenberg DM
Mol Cancer Ther; 2013 Jun; 12(6):968-78. PubMed ID: 23427296
[TBL] [Abstract][Full Text] [Related]
5. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
Stein R; Smith MR; Chen S; Zalath M; Goldenberg DM
Clin Cancer Res; 2009 Apr; 15(8):2808-17. PubMed ID: 19351768
[TBL] [Abstract][Full Text] [Related]
6. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
[TBL] [Abstract][Full Text] [Related]
7. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
Kaufman JL; Niesvizky R; Stadtmauer EA; Chanan-Khan A; Siegel D; Horne H; Wegener WA; Goldenberg DM
Br J Haematol; 2013 Nov; 163(4):478-86. PubMed ID: 24112026
[TBL] [Abstract][Full Text] [Related]
8. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells.
Hertlein E; Triantafillou G; Sass EJ; Hessler JD; Zhang X; Jarjoura D; Lucas DM; Muthusamy N; Goldenberg DM; Lee RJ; Byrd JC
Blood; 2010 Oct; 116(14):2554-8. PubMed ID: 20574049
[TBL] [Abstract][Full Text] [Related]
9. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression.
Frölich D; Blassfeld D; Reiter K; Giesecke C; Daridon C; Mei HE; Burmester GR; Goldenberg DM; Salama A; Dörner T
Arthritis Res Ther; 2012 Mar; 14(2):R54. PubMed ID: 22404985
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.
Martin P; Furman RR; Rutherford S; Ruan J; Ely S; Greenberg J; Coleman M; Goldsmith SJ; Leonard JP
Leuk Lymphoma; 2015; 56(11):3065-70. PubMed ID: 25754579
[TBL] [Abstract][Full Text] [Related]
11. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
[TBL] [Abstract][Full Text] [Related]
12. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.
Mao Y; Triantafillou G; Hertlein E; Towns W; Stefanovski M; Mo X; Jarjoura D; Phelps M; Marcucci G; Lee LJ; Goldenberg DM; Lee RJ; Byrd JC; Muthusamy N
Clin Cancer Res; 2013 Jan; 19(2):347-56. PubMed ID: 23209030
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
14. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
15. Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
Chen X; Chang CH; Stein R; Cardillo TM; Gold DV; Goldenberg DM
Biol Blood Marrow Transplant; 2013 Jan; 19(1):28-39. PubMed ID: 23025988
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies.
Stein R; Qu Z; Cardillo TM; Chen S; Rosario A; Horak ID; Hansen HJ; Goldenberg DM
Blood; 2004 Dec; 104(12):3705-11. PubMed ID: 15297317
[TBL] [Abstract][Full Text] [Related]
17. A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach.
Haran M; Mirkin V; Braester A; Harpaz N; Shevetz O; Shtreiter M; Greenberg S; Mordich O; Amram O; Binsky-Ehrenreich I; Marom A; Shachar I; Herishanu Y; Ruchlemer R; Berrebi A; Valinsky L; Shtalrid M; Shvidel L
Br J Haematol; 2018 Jul; 182(1):125-128. PubMed ID: 28466956
[No Abstract] [Full Text] [Related]
18. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
19. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.
Robak T; Robak E
Expert Opin Investig Drugs; 2014 Jul; 23(7):911-24. PubMed ID: 24708159
[TBL] [Abstract][Full Text] [Related]
20. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin.
Chang CH; Sapra P; Vanama SS; Hansen HJ; Horak ID; Goldenberg DM
Blood; 2005 Dec; 106(13):4308-14. PubMed ID: 16109781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
